As reported on Healio, the U.S. Food and Drug Administration has broadened the indication for roflumilast cream 0.3% (Zoryve, Arcutis), allowing its use in children with plaque psoriasis as young…
Editor's Note: Patient Worthy is honored to share this story from our friends at Elephants & Tea, originally written by Amy Hoffmann — a survivor of triple-negative breast cancer. To…
One of the hardest things about living with dystonia is trying to explain what it feels like on the inside. People often see (not always for some) the muscle contractions, the pulling, the tension…
Editor's Note: Patient Worthy is honored to share this article, provided by our friends at the TREND Community. To see the article in its original format, please click here. Healthcare…
Editor's Note: This article was originally published by Patient Worthy on 6/7/24, and is being republished due to our ongoing efforts to raise awareness of Hidradenitis Suppurativa (HS). The importance…
Editor's Note: This article is brought to you by our friends at the Acromegaly Community, and shared with our audience at their request. To learn more about acromegaly, please visit…
Editor's Note: This article by Tom Seaman was originally shared by Patient Worthy on 12/15/22. I believe very strongly in the power of thoughts and words as it relates to…
A recent BBC report highlighted a forthcoming clinical trial examining puberty-suppressing medications in young people is being positioned by its proponents as a necessary step toward improving patient safety and…
As reported on MedCity News, Eli Lilly has reported encouraging early-stage clinical data for AJ1-11095, an investigational therapy for myelofibrosis acquired through its recent purchase of Ajax Therapeutics. Findings, presented…
My name is Les Howard, and I am living with hypertrophic obstructive cardiomyopathy (HCM). Looking back, I believe I may have lived with HCM for most of my life without knowing…
As reported on PharmaBiz, Sumitomo Pharma America (SMPA) presented new clinical and translational data spanning myelofibrosis (MF) and acute leukemia programs at the 2026 European Hematology Association Congress in Stockholm…
In the United States, colorectal cancer represents the third most frequently diagnosed malignancy and the second leading cause of cancer-related death. A colonoscopy continues to be the gold standard for…
Grifols, as announced in a recent press release, has officially launched FESILTY™ (fibrinogen, human-chmt) in the United States. The therapy is approved to treat sudden, severe bleeding in adults and…
As reported by the BBC, landmark advance in type 1 diabetes care has been reached with the introduction of teplizumab, the first treatment shown to delay the onset of the…
Further to the WHO’s official confirmation of an outbreak of 300 Ebola cases as of May 2026, health authorities in the Democratic Republic of the Congo (DRC) acknowledge one of the…
Every single day, the average person inhales thousands of microscopic fungal spores. For most of us, our immune systems destroy these tiny invaders before they can do any harm. But…
As reported on Scientific American, a growing body of research suggests that Alzheimer’s disease progression is driven by a complex interplay between beta-amyloid plaques and tau neurofibrillary tangles. While both…
Editor’s Note: This story is a continuation of Jenny Decker’s global sailing voyage. To see the original article, please click here. Jenny Decker left Hawaii in 2023 on her vessel Tiama…
Recently at the World Orphan Drug Conference in Boston, Patient Worthy had the opportunity to meet with Dave Pearce PhD, Chair of International Rare Disease Research Consortium, (IRDiRC) Professor of…
As reported on Yahoo News, a combination therapy involving nivolumab (Opdivo) from Bristol Myers Squibb and cabozantinib (Cabometyx) from Exelixis has demonstrated substantial clinical benefit in patients with previously untreated…
Editor's Note: This article was shared with us by our friends at the Courageous Parents Network. To see the article in its original format, please click here. My older sister…
In a recent statement, CONNECTA Therapeutics, a biotechnology company focused on disorders of the central nervous system, has announced the start of its Phase IIa clinical trial for CTH120, a…
As seen in the CDC's recent reports, 0.6 per 100,000 people were hospitalized in mid-April with confirmed hospital admissions averaging between 800 to 900 in June 2026. In addition, the…
As reported on Medscape, global phase 3 clinical trial suggests that veligrotug, an investigational monoclonal antibody targeting the insulin-like growth factor‑1 receptor (IGF‑1R), may offer fast and lasting improvement for…
As reported on Becker's Hospital Review, the U.S. Food and Drug Administration (FDA) has issued updated guidance targeting how telehealth companies promote compounded medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists.…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
